THE BUDGET IMPACT OF USING FIDAXOMICIN FOR HOSPITALISED CDI PATIENTS FROM THE DANISH HEALTH CARE PERSPECTIVE
Author(s)
Nordling S, Cockburn E
Astellas Pharma a/s, Kastrup, Denmark
Presentation Documents
OBJECTIVES: Analyse the budget impact in Region Hovedstaden in Denmark (Region H), if all Clostridium difficile (CDI) hospitalised patients received fidaxomicin instead of vancomycin during one year. METHODS: The Danish national patient database provided the number of hospitalised patients and length of stay (LOS) for CDI patients (ICD-10: A047). A phase III trial provided the risk of a first and second CDI recurrence [Cornelly 2012]. Cost per hospital stay calculated by LOS multiplied by cost per bed day (DKK 6,000) plus drug costs, vancomycin (DKK 300), fidaxomicin (DKK 11,641). RESULTS: In Region H 840 CDI patients were hospitalised in 2012. Assuming the same outcome as the trial, the total number of CDI hospitalisations would decrease from 1,104 with vancomycin ((23,2% risk of 1st recurrence (23.2% *840 = 195); 35.5% risk of 2nd recurrence (35.5%*195 = 69)) to 930 with fidaxomicin ((9.0% risk of 1st recurrence (9.0%*840=76); 19.7% risk of 2nd recurrence (19.7% *76= 15)). Fidaxomicin prevents 174 hospitalisations compared to vancomycin. Assuming CDI is the primary diagnosis, with an average LOS of 9.0 days, the healthcare cost will increase by 2% with fidaxomicin. Assuming CDI is the secondary diagnosis, with an average LOS of 16.8 days, the healthcare cost will decrease by 6% with fidaxomicin. Assuming the average LOS for CDI patients is 13.3 days, the healthcare cost will decrease with 4%, and assuming LOS is 10 days, using fidaxomicin is cost neutral. CONCLUSIONS: In Region H, if all hospitalised CDI patients received fidaxomicin the number of recurrences decreases by 66% and the total number of cases decreases by 16%, compared to vancomycin usage. From the healthcare payer perspective fidaxomicin reduces recurrences, frees up available bed days, and may be cost neutral or cost saving depending on the assumed LOS, compared to vancomycin.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PIN25
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Infectious Disease (non-vaccine)